Key facts
- Kinaset Therapeutics’s last known valuation is $186.0M (Jan 2026).
- It has raised $143.0M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($103.0M) in Jan 2026.
- Notable investors include RA Capital Management, SV Health Investors, EQT Life Sciences, Schroders Capital, Vivo Capital — 12 tracked in total.
- Kinaset Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Jul 2023 ($28.5M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Kinaset Therapeutics
Funding rounds
3 roundsAbout Kinaset Therapeutics
Developer of respiratory drugs designed for novel therapeutics for patients affected by intractable diseases. The company develops inhaled therapeutics to address significant unmet medical needs in respiratory diseases, enabling healthcare providers with a less invasive and cost-effective alternative for treating severe asthma.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Medfield, MA, United States
- Founded
- 2020
- Employees
- 9
- Website
- kinasettherapeutics.com/
- Ownership
- Privately Held (backing)
Kinaset Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kinaset Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kinaset Therapeutics in its N-PORT filings yet. We sweep new filings monthly.